182 related articles for article (PubMed ID: 29051077)
1. Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients.
Ely S; Forsberg P; Ouansafi I; Rossi A; Modin A; Pearse R; Pekle K; Perry A; Coleman M; Jayabalan D; Di Liberto M; Chen-Kiang S; Niesvizky R; Mark TM
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):825-833. PubMed ID: 29051077
[TBL] [Abstract][Full Text] [Related]
2. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
[TBL] [Abstract][Full Text] [Related]
3. Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response.
Sidiqi MH; Aljama MA; Jevremovic D; Morice WG; Timm M; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Gonsalves WI; Kumar S; Kapoor P; Kourelis T; Leung N; Hogan WJ; Muchtar E; Lust JA; Rajkumar VS; Gertz MA
Bone Marrow Transplant; 2019 Mar; 54(3):442-447. PubMed ID: 30087461
[TBL] [Abstract][Full Text] [Related]
4. Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.
Al-Quran SZ; Yang L; Magill JM; Braylan RC; Douglas-Nikitin VK
Hum Pathol; 2007 Dec; 38(12):1779-87. PubMed ID: 17714757
[TBL] [Abstract][Full Text] [Related]
5. Multiplex immunohistochemistry elucidates increased distance between cytotoxic T cells and plasma cells in relapsed myeloma, and identifies Lag-3 as the most common checkpoint receptor on cytotoxic T cells of myeloma patients.
Ninkovic S; Purton LE; Harrison SJ; Quach H
Haematologica; 2024 May; 109(5):1487-1500. PubMed ID: 37855027
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort.
Møller HE; Preiss BS; Pedersen P; Kristensen IB; Hansen CT; Frederiksen M; Abildgaard N; Møller MB
APMIS; 2015 Aug; 123(8):652-8. PubMed ID: 26152595
[TBL] [Abstract][Full Text] [Related]
7. [Determination proliferative activity of myeloma cells in histologic material].
Fabian P; Kren L; Nenutil R
Cesk Patol; 2004 Apr; 40(2):46-9. PubMed ID: 15233016
[TBL] [Abstract][Full Text] [Related]
8. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.
Aljama MA; Sidiqi MH; Lakshman A; Dispenzieri A; Jevremovic D; Gertz MA; Lacy MQ; Buadi FK; Dingli D; Muchtar E; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Warsame R; Kourelis TV; Hwa YL; Kapoor P; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
Blood Adv; 2018 Nov; 2(22):3149-3154. PubMed ID: 30463914
[TBL] [Abstract][Full Text] [Related]
9. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
Hose D; Rème T; Hielscher T; Moreaux J; Messner T; Seckinger A; Benner A; Shaughnessy JD; Barlogie B; Zhou Y; Hillengass J; Bertsch U; Neben K; Möhler T; Rossi JF; Jauch A; Klein B; Goldschmidt H
Haematologica; 2011 Jan; 96(1):87-95. PubMed ID: 20884712
[TBL] [Abstract][Full Text] [Related]
10. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
11. Haematologists usually over-estimate the percentage of CD138+ plasma cells in marrow biopsies.
Chai KY; Boyke Berahmana AA; Morison IM
Pathology; 2019 Oct; 51(6):647-648. PubMed ID: 31470997
[No Abstract] [Full Text] [Related]
12. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
[TBL] [Abstract][Full Text] [Related]
13. Plasma cell maturity as a predictor of prognosis in multiple myeloma.
Iriyama N; Miura K; Hatta Y; Uchino Y; Kurita D; Takahashi H; Sakagami H; Sakagami M; Kobayashi Y; Nakagawa M; Ohtake S; Iizuka Y; Takei M
Med Oncol; 2016 Aug; 33(8):87. PubMed ID: 27383407
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma.
Han W; Jin Y; Xu M; Zhao SS; Shi Q; Qu X; Zhang R; Li J; Wu Y; Chen L
Hematology; 2021 Dec; 26(1):510-517. PubMed ID: 34314294
[TBL] [Abstract][Full Text] [Related]
15. Adverse prognostic impact of bone marrow microvessel density in multiple myeloma.
Lee N; Lee H; Moon SY; Sohn JY; Hwang SM; Yoon OJ; Youn HS; Eom HS; Kong SY
Ann Lab Med; 2015 Nov; 35(6):563-9. PubMed ID: 26354343
[TBL] [Abstract][Full Text] [Related]
16. Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics.
Vagnoni D; Travaglini F; Pezzoni V; Ruggieri M; Bigazzi C; Dalsass A; Mestichelli F; Troiani E; Falcioni S; Mazzotta S; Natale A; Angelini M; Ferretti S; Angelini S; Galieni P
Br J Haematol; 2015 Aug; 170(4):523-31. PubMed ID: 26010293
[TBL] [Abstract][Full Text] [Related]
17. Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
Katodritou E; Terpos E; North J; Kottaridis P; Verrou E; Gastari V; Chadjiaggelidou C; Sivakumaran S; Jide-Banwo S; Tsirogianni M; Kapetanos D; Zervas K; Lowdell MW
Am J Hematol; 2011 Dec; 86(12):967-73. PubMed ID: 21919039
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.
Skrtić A; Korać P; Krišto DR; Ajduković Stojisavljević R; Ivanković D; Dominis M
Hum Pathol; 2010 Dec; 41(12):1702-10. PubMed ID: 20800871
[TBL] [Abstract][Full Text] [Related]
19. Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients.
Al Saleh AS; Parmar HV; Visram A; Muchtar E; Buadi FK; Go RS; Dispenzieri A; Kapoor P; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kourelis TV; Gertz MA; Kyle RA; Rajkumar SV; Kumar SK
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):596-601. PubMed ID: 32360276
[TBL] [Abstract][Full Text] [Related]
20. Correlation of plasma cell percentages by CD138 immunohistochemistry, cyclin D1 status, and CD56 expression with clinical parameters and overall survival in plasma cell myeloma.
Dunphy CH; Nies MK; Gabriel DA
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):248-54. PubMed ID: 17721267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]